AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share (FOLD)

Historical Holders from Q1 2014 to Q3 2025

Symbol
FOLD on Nasdaq
CUSIP
03152W109
Type / Class
Equity / Common Stock, par value $0.01 per share
Shares outstanding
309M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
312M
Holdings value
$2.46B
% of all portfolios
0.005%
Grand Portfolio weight change
0%
Number of holders
277
Number of buys
150
Number of sells
-124
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share (FOLD)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WELLINGTON MANAGEMENT GROUP LLP 9.5% $184M 28.5M Wellington Management Group LLP Dec 31, 2024
BlackRock, Inc. 7.4% -21.1% $148M -$33.3M 22.8M -18.4% BlackRock, Inc. Mar 31, 2025
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 5.2% +6% $126M $9.42M 16M +8.09% WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Sep 30, 2025
Avoro Capital Advisors LLC 4.87% -26.1% $118M -$43.1M 15M -26.7% Avoro Capital Advisors LLC Sep 30, 2025
Redmile Group, LLC 4.6% $91.9M 14.2M Redmile Group, LLC Dec 31, 2024
PERCEPTIVE ADVISORS LLC 2.4% -65.7% $54.9M -$104M 7.41M -65.5% Perceptive Advisors LLC Jun 30, 2025

Institutional Holders of AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share (FOLD)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 312M $2.46B -$41.7M $7.88 277
2025 Q2 319M $1.83B +$26.5M $5.73 268
2025 Q1 309M $2.53B +$26.4M $8.16 280
2024 Q4 305M $2.87B -$29.1M $9.42 285
2024 Q3 307M $3.28B -$104M $10.68 287
2024 Q2 315M $3.13B -$32.3M $9.92 255
2024 Q1 317M $3.74B +$16.4M $11.78 252
2023 Q4 2.04M $29M +$5.45M $14.19 5
2023 Q3 296M $3.6B -$89.7M $12.16 224
2023 Q2 304M $3.81B +$92M $12.56 208
2023 Q1 297M $3.3B +$67.1M $11.09 219
2022 Q4 291M $3.56B +$7.37M $12.21 219
2022 Q3 285M $2.97B -$129M $10.44 213
2022 Q2 287M $3.08B +$13.6M $10.74 194
2022 Q1 270M $2.56B -$16.7M $9.47 195
2021 Q4 299M $3.45B +$92.2M $11.55 210
2021 Q3 293M $2.8B +$155M $9.55 224
2021 Q2 277M $2.67B +$5.14M $9.64 222
2021 Q1 275M $2.72B -$251M $9.88 239
2020 Q4 276M $6.36B +$51M $23.09 262
2020 Q3 277M $3.91B -$60.3M $14.12 234
2020 Q2 281M $4.24B +$8.67M $15.08 212
2020 Q1 281M $2.59B +$73.3M $9.24 184
2019 Q4 273M $2.65B +$16.3M $9.74 205
2019 Q3 270M $2.17B +$42.1M $8.02 190
2019 Q2 268M $3.35B +$271M $12.48 197
2019 Q1 250M $3.4B +$287M $13.60 193
2018 Q4 228M $2.18B +$17.6M $9.58 175
2018 Q3 225M $2.72B +$35.8M $12.09 194
2018 Q2 221M $3.46B +$48.7M $15.62 194
2018 Q1 225M $3.38B +$287M $15.04 197
2017 Q4 206M $2.96B +$69.1M $14.39 179
2017 Q3 198M $2.99B +$374M $15.08 180
2017 Q2 174M $1.75B +$127M $10.07 136
2017 Q1 169M $1.2B +$168M $7.13 128
2016 Q4 157M $780M +$23.5M $4.97 130
2016 Q3 148M $1.1B +$113M $7.40 134
2016 Q2 137M $748M -$24.9M $5.46 124
2016 Q1 139M $1.17B +$7.44M $8.45 125
2015 Q4 139M $1.35B +$34.3M $9.70 136
2015 Q3 127M $1.75B +$192M $13.99 142
2015 Q2 112M $1.59B +$450M $14.15 133
2015 Q1 82M $890M +$47.7M $10.88 124
2014 Q4 79.5M $662M +$234M $8.32 107
2014 Q3 46.8M $278M +$45.5M $5.95 93
2014 Q2 40M $134M +$27M $3.34 59
2014 Q1 34.3M $71M -$354K $2.07 67